Cargando…
Treatment With Erythropoietin for Patients With Optic Neuritis: Long-term Follow-up
BACKGROUND AND OBJECTIVE: Erythropoietin (EPO) is a candidate neuroprotective drug. We assessed its long-term safety and efficacy as an adjunct to methylprednisolone in patients with optic neuritis and focused on conversions to multiple sclerosis (MS). METHODS: The TONE trial randomized 108 patients...
Autores principales: | Küchlin, Sebastian, Ihorst, Gabriele, Grotejohann, Birgit, Beisse, Flemming, Heinrich, Sven P., Albrecht, Philipp, Ungewiss, Judith, Wörner, Michael, Hug, Martin J., Wolf, Sebastian, Diem, Ricarda, Lagrèze, Wolf A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136679/ https://www.ncbi.nlm.nih.gov/pubmed/37094997 http://dx.doi.org/10.1212/NXI.0000000000200067 |
Ejemplares similares
-
Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial—study protocol
por: Diem, Ricarda, et al.
Publicado: (2016) -
Disease Activity and Conversion into Multiple Sclerosis after Optic Neuritis Is Treated with Erythropoietin
por: Sühs, Kurt-Wolfram, et al.
Publicado: (2016) -
Erythropoietin for Optic Neuritis
por: Foroozan, Rod
Publicado: (2019) -
First Description of Inheritance of a Postzygotic OPA1 Mosaic Variant
por: Alter, Svenja, et al.
Publicado: (2022) -
Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, controlled, double-blind, multicentre, clinical trial with two parallel arms
por: Farassat, Navid, et al.
Publicado: (2023)